Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 783-786

  Unadkat, Jashvant D ^a   Wara, Diane W ^b   Hughes, Michael D ^c   Mathias, Anita A ^a   Holland, Diane T ^d   Paul, Mary E ^e   Connor, James ^d   Huang, Sharon ^c   Nguyen, Bach Yen ^f   Watts, D Heather ^g   Mofenson, Lynne M ^g   Smith, Elizabeth ^h   Deutsch, Paul ^f   Kaiser, Kathleen A ⁱ   Tuomala, Ruth E ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CRYSTALLURIA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLANK PAIN; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFANT; INFECTION PREVENTION; LOW BIRTH WEIGHT; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; NEWBORN; PERINATAL PERIOD; PREGNANCY; PREMATURITY; PRENATAL PERIOD; PRIORITY JOURNAL; PYELONEPHRITIS; VERTICAL TRANSMISSION; VOMITING;

ADULT; CYTOCHROME P-450 CYP3A; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; INFANT, NEWBORN; LIVER; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 33846629858     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00420-06     Document Type: Article

References (13)

1. AIDS Clinical Trials Group. 1996. Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD.
2. Back, D., G. Gatti, C. Fletcher, R. Garaffo, R. Haubrich, R. Hoetelmans, M. Kurowski, A. Luber, C. Merry, and C. F. Perno. 2002. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1):S5-S37.
3. Bean, P. 2000. HIVs pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Am. Clin. Lab. 19:12.
4. Centers For Disease Control and Prevention. 1998. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morb. Mortal. Wkly. Rep. 47:1-20.
5. Choo, E. F., B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. R. Wilkinson, and R. B. Kim. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655-660.
6. Clevenbergh, P., S. Mouly, P. Sellier, E. Badsi, J. Cervoni, V. Vincent, H. Trout, and J. F. Bergmann. 2004. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr. HIV Res. 2:309-321.
7. Connor, E. M., R. S. Sperling, R. Gelber, P. Kiselev, G. Scott, M. J. O'Sullivan, R. VanDyke, M. Bey, W. Shearer, R. L. Jacobson, E. Jimenez, E. O'Neill, B. Bazin, J. F. Delfraissy, M. Culnane, R. Coombs, M. Elkins, J. Moye, P. Stratton, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1173-1180.
8. Frederiksen, M. 2001. Physiologic changes in pregnancy and their effect on drug disposition. Semin. Perinatol. 25:120-123.
9. Mathias, A. A., L. Maggio-Price, Y. Lai, A. Gupta, and J. D. Unadkat. 2006. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein. J. Pharmacol. Exp. Ther. 3:1202-1209.
10. Rey, E., P. d'Athis, P. Giraux, D. de Lauture, J. M. Turquais, J. Chavinie, and G. Olive. 1979. Pharmacokinetics of clorazepate in pregnant and non-pregnant women. Eur. J. Clin. Pharmacol. 15:175-180.
11. Tracy, T. S., R. Venkataramanan, D. D. Glover, and S. N. Caritis. 2005. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol. 192:633-639.
12. Unadkat, J. D., and Y. Wang. 2000. Antivirals, p. 421-433. In R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hnasten, and M. Eichelbaum (ed.), Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, PA.
13. Vibhagool, A., P. Cahn, M. Schechter, F. Smaill, L. Soto-Ramirez, G. Carosi, M. Montroni, C. E. Pharo, J. C. Jordan, N. E. Thomas, and G. Pearce. 2004. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr. Med. Res. Opin. 20:1103-1114.